سعر جينيكسول 6مجم/مل (100 مجم) محلول وريدي 2022

Paclitaxel 6 mg/mL concentrate for intravenous infusion (100 mg vial), a taxane cytotoxic chemotherapy made by Samyang (Korea) and promoted in Egypt by the Egyptian Promotion Center.

• Ovarian cancer: first-line treatment in combination with cisplatin for advanced disease, and subsequent therapy for metastatic disease after failure of first-line or later chemotherapy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Breast cancer: adjuvant treatment of node-positive disease given sequentially after doxorubicin-containing combination chemotherapy, and treatment after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Non-small cell lung cancer: first-line treatment in combination with cisplatin in patients who are not candidates for potentially curative surgery and/or radiation therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• History of severe hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil (US product excipient).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Solid tumours with baseline neutrophils below 1,500 cells/mm3, or AIDS-related Kaposi's sarcoma with baseline neutrophils below 1,000 cells/mm3.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: anaphylaxis and severe hypersensitivity reactions (dyspnoea and hypotension requiring treatment, angioedema, generalised urticaria) occurred in 2-4% of patients in clinical trials, with fatal reactions despite premedication; premedicate all patients and do not rechallenge after a severe reaction.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: do not administer to patients with baseline neutrophil counts below 1,500 cells/mm3 (below 1,000 cells/mm3 in AIDS-related Kaposi's sarcoma); monitor blood counts frequently because bone marrow suppression is the major dose-limiting toxicity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CisplatinWhen given in combination, paclitaxel should be given before cisplatin; cisplatin given first reduces paclitaxel clearance and increases myelosuppression.DailyMed (U.S. National Library of Medicine)
• CYP2C8 and CYP3A4 inhibitors or inducersPaclitaxel is metabolised by CYP2C8 and CYP3A4; use caution with drugs that inhibit or induce these enzymes.DailyMed (U.S. National Library of Medicine)

• Because of the potential for serious adverse reactions in nursing infants, nursing should be discontinued during paclitaxel therapy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Paclitaxel: Antimicrotubule agent that promotes microtubule assembly by enhancing tubulin polymerisation, forming stable non-functional microtubules and disrupting the dynamic equilibrium of the microtubule system needed for mitosis.